Illuma的股票跌到52周的低点, 尽管“Moderate Buy”评级为“Moderate Buy”, 目标价格更高。 Illumina's stock hits a 52-week low, despite having a "Moderate Buy" rating with a higher price target.

生命科学公司Illuma在2月14日创下52周的新低点, 股票交易量低达76.63美元。 Illumina, a life sciences company, hit a new 52-week low on February 14th, with shares trading as low as $76.63. 尽管收入估计数缺失,最近股票下跌,但该公司的评级是“Moderate Buy”,平均价格目标为140.90美元。 Despite missing earnings estimates and a recent stock drop, the company has a "Moderate Buy" rating and an average price target of $140.90. 在最后一个季度,马萨诸塞州金融服务公司在Illumina的股票头寸减少了22.6%。 Massachusetts Financial Services reduced its stock position in Illumina by 22.6% in the last quarter.